Pavion Blue Capital LLC Takes $260,000 Position in Pfizer Inc. (NYSE:PFE)

Pavion Blue Capital LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 8,999 shares of the biopharmaceutical company’s stock, valued at approximately $260,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Olistico Wealth LLC bought a new stake in Pfizer in the second quarter valued at $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer in the second quarter valued at $29,000. Quarry LP bought a new stake in Pfizer in the second quarter valued at $31,000. Trivant Custom Portfolio Group LLC grew its position in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares during the period. Finally, Financial Connections Group Inc. bought a new stake in Pfizer in the second quarter valued at $34,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have weighed in on PFE shares. Sanford C. Bernstein started coverage on Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Barclays boosted their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Trading Down 0.6 %

Shares of PFE opened at $28.46 on Friday. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54. The firm has a market capitalization of $161.27 billion, a PE ratio of -61.87, a price-to-earnings-growth ratio of 1.01 and a beta of 0.67. The stock’s fifty day simple moving average is $29.07 and its 200-day simple moving average is $28.49.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.67 earnings per share. As a group, research analysts predict that Pfizer Inc. will post 2.67 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 5.90%. Pfizer’s dividend payout ratio is presently -365.21%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.